This is a demo store. No orders will be fulfilled.

 
Call +1 (833) 552-7181 or Contact us
Toggle Nav
My Cart
Search
Advanced Search
Menu
Account
Settings
྾
main product photo

Gemcitabine - ≥99%, high purity , CAS No.95058-81-4, Inhibitor of ribonucleotide reductase catalytic subunit M1;Inhibitor of ribonucleotide reductase regulatory subunit M2

28 Citations COA COA
In stock
Item Number
G127944
Grouped product items
SKU Size
Availability
 Price Qty
G127944-50mg
50mg
3
$9.90
G127944-100mg
100mg
3
$11.90
G127944-250mg
250mg
3
$18.90
G127944-1g
1g
2
$56.90
G127944-5g
5g
1
$199.90
G127944-10g
10g
Available within 4-8 weeks(?)
Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience!
$319.90
G127944-25g
25g
3
$629.90
G127944-100g
100g
2
$1,499.90
Wish List
Bulk Order  SDS  DATASHEET  Specification Sheet

Cytidine analog. Antimetabolite.

View related series
Apoptosis (4276) Autophagy (1917) Cell Cycle (2830) Cell Cycle/DNA Damage (2602) DNA/RNA Synthesis (362) Nucleoside Antimetabolite/Analog (200) Nucleosides (90) ribonucleotide reductase catalytic subunit M1 Inhibitor (5) ribonucleotide reductase regulatory subunit M2 Inhibitor (4)

Basic Description

Synonyms 2'-Deoxy-2',2'-difluorocytidine | 2',2'-Difluorodeoxycytidine
Specifications & Purity Moligand™, ≥99%
Biochemical and Physiological Mechanisms Gemcitabine is a widely used antitumor agents in both clinics and research labs. It is an antineoplastic agent and antimetabolite. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCT
Storage Temp Store at -20°C
Shipped In
Ice chest + Ice pads
This product requires cold chain shipping. Ground and other economy services are not available.
Grade Moligand™
Action Type INHIBITOR
Mechanism of action Inhibitor of ribonucleotide reductase catalytic subunit M1;Inhibitor of ribonucleotide reductase regulatory subunit M2
Note Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour. Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
Product Description

2'-Deoxy-2',2'-difluorocytidine is an irreversible inactivator of R1 and R2 (ribonucleoside diphosphate reductase, RDPR) from Escherichia coli.
Soluble in ethanol (~0.25 mg/ml), DMSO (15 mg/ml at 25 °C), DMF (~0.1 mg/ml), water (<1 mg/ml at 25 °C), and PBS pH 7.2 (~2 mg/ml).
An irreversible inactivator of bacterial ribonucleoside diphosphate reductase.

Taxonomic Classification

Taxonomy Tree

Kingdom Organic compounds
Superclass Nucleosides, nucleotides, and analogues
Class Pyrimidine nucleosides
Subclass Pyrimidine 2'-deoxyribonucleosides
Intermediate Tree Nodes Not available
Direct Parent Pyrimidine 2'-deoxyribonucleosides
Alternative Parents Pyrimidones  Aminopyrimidines and derivatives  Hydropyrimidines  Imidolactams  Tetrahydrofurans  Heteroaromatic compounds  Secondary alcohols  Fluorohydrins  Azacyclic compounds  Oxacyclic compounds  Organic oxides  Hydrocarbon derivatives  Organofluorides  Organopnictogen compounds  Primary alcohols  Primary amines  Alkyl fluorides  
Molecular Framework Aromatic heteromonocyclic compounds
Substituents Pyrimidine 2'-deoxyribonucleoside - Aminopyrimidine - Pyrimidone - Hydropyrimidine - Pyrimidine - Imidolactam - Heteroaromatic compound - Tetrahydrofuran - Fluorohydrin - Halohydrin - Secondary alcohol - Organoheterocyclic compound - Azacycle - Oxacycle - Alkyl halide - Organopnictogen compound - Primary amine - Primary alcohol - Organooxygen compound - Organonitrogen compound - Organofluoride - Organohalogen compound - Organic oxygen compound - Alkyl fluoride - Alcohol - Organic nitrogen compound - Amine - Organic oxide - Hydrocarbon derivative - Aromatic heteromonocyclic compound
Description This compound belongs to the class of organic compounds known as pyrimidine 2'-deoxyribonucleosides. These are compounds consisting of a pyrimidine linked to a ribose which lacks a hydroxyl group at position 2.
External Descriptors organofluorine compound - pyrimidine 2'-deoxyribonucleoside

Associated Targets(Human)

SLC29A1 Tclin Equilibrative nucleoside transporter 1 (1 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
RRM1 Tclin Ribonucleoside-diphosphate reductase large subunit (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
RRM2 Tclin Ribonucleoside-diphosphate reductase subunit M2 (0 Activities)
Activity Type Activity Value -log(M) Mechanism of Action Activity Reference Publications (PubMed IDs)
PDE5A Tclin Phosphodiesterase 5A (5113 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EGFR Tclin Epidermal growth factor receptor erbB1 (33727 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CA2 Tclin Carbonic anhydrase II (17698 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ESR1 Tclin Estrogen receptor alpha (17718 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HMGCR Tclin HMG-CoA reductase (2475 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
NR3C1 Tclin Glucocorticoid receptor (14987 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
INSR Tclin Insulin receptor (5558 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PGR Tclin Progesterone receptor (8562 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRB2 Tclin Beta-2 adrenergic receptor (11824 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CHRM2 Tclin Muscarinic acetylcholine receptor M2 (10671 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRB1 Tclin Beta-1 adrenergic receptor (6630 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR1A Tclin Serotonin 1a (5-HT1a) receptor (14969 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA2A Tclin Alpha-2a adrenergic receptor (9450 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AR Tclin Androgen Receptor (11781 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CHRM1 Tclin Muscarinic acetylcholine receptor M1 (12690 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ACE Tclin Angiotensin-converting enzyme (1423 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
DRD2 Tclin Dopamine D2 receptor (23596 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
GABRA1 Tclin GABA receptor alpha-1 subunit (399 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
MAOA Tclin Monoamine oxidase A (11911 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CNR1 Tclin Cannabinoid CB1 receptor (20913 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
DRD1 Tclin Dopamine D1 receptor (9720 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
DRD4 Tchem Dopamine D4 receptor (7907 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ACHE Tclin Acetylcholinesterase (18204 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PTGS1 Tclin Cyclooxygenase-1 (9233 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
RRM1 Tclin Ribonucleoside-diphosphate reductase M1 chain (163 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SLC6A2 Tclin Norepinephrine transporter (10102 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HRH2 Tclin Histamine H2 receptor (5428 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA1D Tclin Alpha-1d adrenergic receptor (4171 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR1B Tclin Serotonin 1b (5-HT1b) receptor (2801 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR2A Tclin Serotonin 2a (5-HT2a) receptor (14758 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR2C Tclin Serotonin 2c (5-HT2c) receptor (11471 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AVPR2 Tclin Vasopressin V2 receptor (2912 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADORA1 Tclin Adenosine A1 receptor (17603 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AGTR1 Tclin Type-1 angiotensin II receptor (5176 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CALCR Tclin Calcitonin receptor (2215 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SLC6A4 Tclin Serotonin transporter (12625 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA1A Tclin Alpha-1a adrenergic receptor (8359 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
PTGS2 Tclin Cyclooxygenase-2 (13999 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HRH1 Tclin Histamine H1 receptor (7573 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
ADRA1B Tclin Alpha-1b adrenergic receptor (2912 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
OPRM1 Tclin Mu opioid receptor (19785 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
DRD3 Tclin Dopamine D3 receptor (14368 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
AVPR1A Tclin Vasopressin V1a receptor (5412 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
OPRD1 Tclin Delta opioid receptor (15096 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
OPRK1 Tclin Kappa opioid receptor (16155 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR3A Tclin Serotonin 3a (5-HT3a) receptor (3366 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SLC6A3 Tclin Dopamine transporter (10535 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
GRIN1 Tclin Glutamate (NMDA) receptor subunit zeta 1 (122 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
KCNH2 Tclin HERG (29587 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
HTR4 Tclin Serotonin 4 (5-HT4) receptor (2068 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Associated Targets(non-human)

Agtr2 Angiotensin II type 2 (AT-2) receptor (803 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mc4r Melanocortin receptor 4 (1205 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Ltc4s Leukotriene C4 synthase (1 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Sigmar1 Sigma opioid receptor (160 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Cda Cytidine deaminase (37 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Npy1r Neuropeptide Y receptor type 1 (8 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Cckar Cholecystokinin A receptor (90 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Pde4d Phosphodiesterase 4D (4 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Abcb1b P-glycoprotein 1 (174 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Nos2 Nitric oxide synthase, inducible (3573 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mmp9 Matrix metalloproteinase 9 (38 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Enterovirus C (520 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Staphylococcus aureus (210822 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Escherichia coli (133304 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Streptococcus sp. (212 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Streptococcus pyogenes (16140 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Human alphaherpesvirus 3 (4092 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Mus musculus (284745 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Rattus norvegicus (775804 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Human immunodeficiency virus 1 (70413 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
rhinovirus A1B (360 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Hepatitis C virus (23859 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Influenza A virus (11224 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CV-1 (316 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
EL4 (235 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
L1210 (27553 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
RAW264.7 (28094 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Vero (26788 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
TRAMP-C1A (16 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
C2D cell line (11 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
C2G cell line (11 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
TRAMP-C2H (17 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
C6 (2371 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
H4 (48 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
H22 (575 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
4T1 (1737 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
B16-F10 (4610 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
MAT-Ly-Lu (18 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
CT26 (928 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
dak Deoxyadenosine kinase (12 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Blood (6 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Serum (58 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Slc22a5 Solute carrier family 22 member 5 (44 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Glra2 Glycine receptor (1745 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Middle East respiratory syndrome-related coronavirus (220 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
Zika virus (1028 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity Type Relation Activity value Units Action Type Journal PubMed Id doi Assay Aladdin ID

Mechanisms of Action

Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References

Names and Identifiers

Pubchem Sid 504753715
Pubchem Sid Url https://pubchem.ncbi.nlm.nih.gov/substance/504753715
IUPAC Name 4-amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
INCHI InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1
InChIKey SDUQYLNIPVEERB-QPPQHZFASA-N
Smiles C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)(F)F
Isomeric SMILES C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F
Alternate CAS 122111-03-9
Molecular Weight 263.2
Reaxy-Rn 11499718
Reaxys-RN_link_address https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=11499718&ln=

Certificates（CoA,COO,BSE/TSE and Analysis Chart)

C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

34 results found

Lot Number Certificate Type Date Item
H2316110 Certificate of Analysis May 12, 2025 G127944
E2330122 Certificate of Analysis Mar 05, 2025 G127944
F2301019 Certificate of Analysis Mar 04, 2025 G127944
E2528151 Certificate of Analysis Jul 05, 2024 G127944
G2426375 Certificate of Analysis Jul 05, 2024 G127944
G2426376 Certificate of Analysis Jul 05, 2024 G127944
G2426392 Certificate of Analysis Jul 05, 2024 G127944
D2525004 Certificate of Analysis Jul 05, 2024 G127944
K2404403 Certificate of Analysis Jul 05, 2024 G127944
F2223305 Certificate of Analysis May 09, 2024 G127944
F2223277 Certificate of Analysis May 09, 2024 G127944
F2223304 Certificate of Analysis Apr 03, 2024 G127944
F2419055 Certificate of Analysis Mar 28, 2024 G127944
G2408023 Certificate of Analysis Mar 28, 2024 G127944
D2412464 Certificate of Analysis Mar 28, 2024 G127944
D2412466 Certificate of Analysis Mar 28, 2024 G127944
D2412468 Certificate of Analysis Mar 28, 2024 G127944
D2412470 Certificate of Analysis Mar 28, 2024 G127944
D2412472 Certificate of Analysis Mar 28, 2024 G127944
C2421406 Certificate of Analysis Mar 11, 2024 G127944
L2318465 Certificate of Analysis Dec 01, 2023 G127944
L2318466 Certificate of Analysis Dec 01, 2023 G127944
L2318467 Certificate of Analysis Dec 01, 2023 G127944
L2318468 Certificate of Analysis Dec 01, 2023 G127944
L2106531 Certificate of Analysis Sep 19, 2023 G127944
L2106534 Certificate of Analysis Sep 19, 2023 G127944
L2106600 Certificate of Analysis Sep 19, 2023 G127944
L2106533 Certificate of Analysis Sep 19, 2023 G127944
C2130218 Certificate of Analysis Jan 13, 2023 G127944
C2130220 Certificate of Analysis Jan 13, 2023 G127944
K1819040 Certificate of Analysis Jul 18, 2022 G127944
F2223303 Certificate of Analysis Jun 01, 2022 G127944
G2311070 Certificate of Analysis Jun 01, 2022 G127944
K2327045 Certificate of Analysis Jun 01, 2022 G127944

Show more⌵

Chemical and Physical Properties

Solubility DMSO 15 mg/mL Water <1 mg/mL Ethanol <1 mg/mL
Sensitivity Heat sensitive
Specific Rotation[α] 74° (C=1,MeOH)
Melt Point(°C) 217-222°C
Molecular Weight 263.200 g/mol
XLogP3 -1.500
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 6
Rotatable Bond Count 2
Exact Mass 263.072 Da
Monoisotopic Mass 263.072 Da
Topological Polar Surface Area 108.000 Ų
Heavy Atom Count 18
Formal Charge 0
Complexity 426.000
Isotope Atom Count 0
Defined Atom Stereocenter Count 3
Undefined Atom Stereocenter Count 0
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
The total count of all stereochemical bonds 0
Covalently-Bonded Unit Count 1

Alternative Products

  1. no_selection
    Gemcitabine (LY-188011), Inhibitor of ribonucleotide reductase catalytic subunit M1;Inhibitor of ribonucleotide reductase regulatory subunit M2

    Starting at $46.90

Citations of This Product

How to Cite Aladdin Scientific Products?
1. Dongchao Xu, Ajuan Liu, Qiang Liu, Hongchen Zhang, Mengyao Tian, Ying Bian, Xiaofeng Zhang, Meidan Ying, Hongzhang Shen.  (2023)  Cucurbitacin C suppresses the progression of pancreatic ductal adenocarcinoma via inhibition of the cGMP-PKG-VASP axis.  BIOCHEMICAL PHARMACOLOGY,  217  (115810). 
2. Yifan Luo, Chao Li, Yiwen Zhang, Peixin Liu, Hongyi Chen, Zhenhao Zhao, Yu Wang, Zheng Zhou, Haolin Song, Boyu Su, Chufeng Li, Xuwen Li, Tongyu Zhang, Haoyu You, Yuxing Wu, Zonghua Tian, Shilin Zhang, Yun Guo, Hongrui Fan, Qinjun Chen, Chen Jiang, Tao Sun.  (2023)  Gradient tumor microenvironment-promoted penetrating micelles for hypoxia relief and immunosuppression reversion in pancreatic cancer treatment.  Acta Biomaterialia,     
3. Nan Zhang, Junwei Zhang, Weiqi Cui, Deqiao Wu, Jingxian Zhang, Bo Wei, Lingbo Qu, Xia Xu.  (2023)  Artemisia argyi H.Lév. & Vaniot essential oil induces ferroptosis in pancreatic cancer cells via up-regulation of TFR1 and depletion of γ-glutamyl cycle.  FITOTERAPIA,  168  (105522). 
4. Zhuo Yao, Qida Hu, Piaopiao Jin, Bowen Li, Yong Huang, Fu Zhang, Meng Wang, Junming Huang, Jing Huang, Shiyi Shao, Xinyu Zhao, Yuan Ping, Tingbo Liang.  (2023)  A Self-Assembly Combined Nano-Prodrug to Overcome Gemcitabine Chemo-Resistance of Pancreatic Tumors.  ADVANCED FUNCTIONAL MATERIALS,    (2214598). 
5. Fu Zhang, Zhuo Yao, Piaopiao Jin, Mengqiu Xu, Qida Hu, Yuxuan Chen, Risheng Que, Tingbo Liang.  (2023)  A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.  Biomedical Materials,  18  (3): (35010). 
6. Fu Zhang, Qida Hu, Bowen Li, Yong Huang, Meng Wang, Shiyi Shao, Honglin Tang, Zhuo Yao, Yuan Ping, Tingbo Liang.  (2023)  A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors.  JOURNAL OF CONTROLLED RELEASE,  354  (835). 
7. Hao Chi, Sheng Tian, Xiu Li, Yuchu Chen, Qiumin Xu, Qixiao Wang, Wenwan Shi, Michael Adu-Frimpong, Shanshan Tong.  (2023)  Construction of lipid raft-coupled agarose gels as bioaffinity chromatography materials and validation with tropomyosin-related kinase A-targeted drugs.  JOURNAL OF CHROMATOGRAPHY A,  1691  (463803). 
8. Yaowei Guo, Jin Liu, Qinglin Tang, Cuicui Li, Yanying Zhang, Yao Wang, Yanxin Wang, Yupeng Bi, Christopher D. Snow, Matt J. Kipper, Laurence A. Belfiore, Jianguo Tang.  (2022)  Lanthanide (Eu3+/Tb3+)-Loaded γ-Cyclodextrin Nano-Aggregates for Smart Sensing of the Anticancer Drug Irinotecan.  INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES,  23  (12): (6597). 
9. Yuting Zhu, Shanhao Han, Jianhui Li, Hongwei Gao, Bo Dong.  (2022)  Aqueous Extract of Sea Squirt (Halocynthia roretzi) with Potent Activity against Human Cancer Cells Acts Synergistically with Doxorubicin.  Marine Drugs,  20  (5): (284). 
10. Chen Ting-ting, Yuan Ming-ming, Tao Yu-mei, Ren Xiao-yan, Li Sufen.  (2022)  Engineering of Self-assembly Polymers Encapsulated with Dual Anticancer Drugs for the Treatment of Endometrial Cancer.  JOURNAL OF CLUSTER SCIENCE,  33  (6): (2661-2671). 
11. Yingjie Kong, Yeneng Dai, Dashan Qi, Wenyu Du, Haiyang Ni, Fan Zhang, Honghai Zhao, Qingming Shen, Meixing Li, Quli Fan.  (2021)  Injectable and Thermosensitive Liposomal Hydrogels for NIR-II Light-Triggered Photothermal-Chemo Therapy of Pancreatic Cancer.  ACS Applied Bio Materials,  4  (10): (7595–7604). 
12. Xiaoyu Xu, Zishan Zeng, Xin Ding, Ting Shan, Qiuxing Liu, Meixu Chen, Jie Chen, Meng Xia, Yuanfeng He, Zeqian Huang, Yanjuan Huang, Chunshun Zhao.  (2021)  Reactive oxygen species-activatable self-amplifying Watson-Crick base pairing-inspired supramolecular nanoprodrug for tumor-specific therapy.  BIOMATERIALS,  277  (121128). 
13. Cui Jing, Guo Yao, Wu Heshui, Xiong Jiongxin, Peng Tao.  (2021)  Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.  MOLECULAR MEDICINE,  27  (1): (1-16). 
14. Feng Fan, Lijun Jin, Lihua Yang.  (2021)  pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer.  ACS Applied Materials & Interfaces,  13  (11): (12824–12835). 
15. Xin Zhang, Jiapeng Xu, Ronglin Yan, Yu Zhang, Zunqi Hu, Hongbing Fu, Qing You, Qingping Cai, Dejun Yang.  (2020)  FAM84B, amplified in pancreatic ductal adenocarcinoma, promotes tumorigenesis through the Wnt/β-catenin pathway.  Aging-US,  12  (8): ( 6808–6822). 
16. Jing Dai, Yiqun Wang, Dinghao Wu, Fengju Wan, Yi Lu, Na Kong, Xiuchun Li, Jinkang Gong, Shengjie Ling, Yuan Yao.  (2020)  Biointerface mediates cytoskeletal rearrangement of pancreatic cancer cell and modulates its drug sensitivity.  Colloid and Interface Science Communications,  35  (100250). 
17. Yan Liang, Jing Zhang, Baocheng Tian, Zimei Wu, Darren Svirskis, Jingtian Han.  (2020)  A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.  International Journal of Nanomedicine,     
18. Lin Xiao-mian, Luo Wu, Wang Heng, Li Rong-zhen, Huang Yi-shan, Chen Lian-kuai, Wu Xiao-ping.  (2019)  The Role of Prostaglandin-Endoperoxide Synthase-2 in Chemoresistance of Non-Small Cell Lung Cancer.  Frontiers in Pharmacology,  10  (836). 
19. Liu Yue, Lu Shan, Zhao Liang, Dong Xin, Zhu Zhenyu, Jin Yongsheng, Chen Haisheng, Lu Feng, Hong Zhanying, Chai Yifeng.  (2018)  Effects of glaucocalyxin A on human liver cancer cells as revealed by GC/MS- and LC/MS-based metabolic profiling.  ANALYTICAL AND BIOANALYTICAL CHEMISTRY,  410  (14): (3325-3335). 
20. Tingyu Yu, Jiao Lin, Jin Zhao, Wei Huang, Lingwen Zeng, Zhiyuan Fang, Ning Xu.  (2017)  A simple in vitro tumor chemosensitivity assay based on cell penetrating peptide tagged luciferase.  PLoS One,  12  (11): (e0186184). 
21. Peng-fei Liu, Yan-wei Cao, Shu-dong Zhang, Yang Zhao, Xiao-guang Liu, Hao-qing Shi, Ke-yao Hu, Guan-qun Zhu, Bo Ma, Hai-tao Niu.  (2015)  A bladder cancer microenvironment simulation system based on a microfluidic co-culture model.  Oncotarget,  6  (35): ( 37695–37705). 
22. Hong Jiawei, Xian Shiyun, Zheng Shusen, Wang Hangxiang, Jiang Donghai.  (2024)  Addressing chemoresistance with a lipid gemcitabine nanotherapeutic strategy for effective treatment of pancreatic cancer.  Nano Research,    (1-12). 
23. Zheng Rongji, Guan Tian, Hong Chaoqun, Yao Yao, Fang Yutong, Huang Wei, Chen Chunfa, Zeng Huancheng, Huang Jiman, Lin Hui, Chen Bingfeng, Zhang Rendong, Chen Dongmei, Ding Zhechun, Zeng Haoyu, Wu Jundong.  (2024)  C188-9 reduces patient-specific primary breast cancer cells proliferation at the low, clinic-relevant concentration.  Journal of Translational Medicine,  22  (1): (1-9). 
24. Qida Hu, Fu Zhang, Bowen Li, Piaopiao Jin, Junming Huang, Zhuo Yao, Xinyu Zhao, Shiyi Shao, Meng Wang, Yuan Ping, Tingbo Liang.  (2025)  Engineered a Gemcitabine Nano-Prodrug Targeting Desmoplastic Pancreatic Tumor with Dual Enhancement of Penetration Dynamics.  Small,    (2410629). 
25. Yuanxin Pian, Yan Hao, Yuxin Guo, Shiqi Wu, Saijiao Tang, Jiaqi Li, Xinya Lu, Xiaoya Sun, Zhaowen Tan, Tianyu Zhu, Yuxiang Tang, Defeng Xu, Hang Hu.  (2025)  Exploration of using α-crocin for drug encapsulation and delivery.  JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY,  106  (106716). 
26. Qinglian Hu, Jiayu Feng, Lulu Qi, Yuanxiang Jin.  (2024)  Stromal Reprogramming Optimizes KRAS-Specific Chemotherapy Inducing Antitumor Immunity in Pancreatic Cancer.  ACS Applied Materials & Interfaces,  16  (45): (61583-61598). 
27. Lihong Chen, Zijia Zhao, Rominah Onintsoa Diarimalala, Zhongwei Chen, Yu Wang, Taozhu Zhan, Yanchao Zhao, Chunhui Ma, Xingyue Wang, Chenqi Zhao, Zicheng Xiao, Kanghong Hu, Pingfan Wu.  (2024)  Tris-functionalized polyoxotungstovanadate-mediated antitumor efficacy involves multiple cell death pathways.  CHEMISTRY & BIODIVERSITY,    (e202301898). 
28. Hongzi Wu, Bowen Li, Jichun Shao, Qingquan Kong.  (2024)  Tumor-oriented and chemo-photothermal nanoplatform capable of sensitizing chemotherapy and ferroptosis against osteosarcoma metastasis.  INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES,    (132019). 

Solution Calculators

Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.